Mobile App

Google Play Apple Store
What's New Doc? End-of-the-Year Updates on CAR T-cell Therapy in Multiple Myeloma
AMA/ABS/ANCC/ACPE - Video
CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.
Click 'Continue to Activity' to begin and claim up to 0.50 AMA, ABS, ANCC, or ACPE credit/contact hour(s) after completion.
Joseph Mikhael, MD

Joseph Mikhael, MD

Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation

You Might be Interested in...

What's New Doc? End-of-the-Year Updates on CAR T-cell Therapy in Multiple Myeloma
AMA/ABS/ANCC/ACPE - Video

Joseph Mikhael, MD

Joseph Mikhael, MD

Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.
Click 'Continue to Activity' to begin and claim up to 0.50 AMA, ABS, ANCC, or ACPE credit/contact hour(s) after completion.
Joseph Mikhael, MD

Joseph Mikhael, MD

Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation



You Might be Interested in...


 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.

What's New Doc? End-of-the-Year Updates on CAR T-cell Therapy in Multiple Myeloma

AMA/ABS/ANCC/ACPE - Video
1 episode | 0.50 credit hours

Joseph Mikhael, MD

Joseph Mikhael, MD

Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation

You Might be Interested in...


20
Supported by independent educational grants from
Johnson & Johnson and Legend Biotech

Launch/Release Date: December 15, 2025
Activity Expiration Date: November 30, 2026

Multipage
8043
CART2025700.png
False
  • Hematology
Hematology
Change Settings